Novo submits sickle cell drug for regulatory approvalNovo Nordisk has submitted a sickle cell disease drug for regulatory approval, a medicine acquired in a billion-dollar deal that the company views as a future blockbuster.Nov 13, 2026·2 sourcesClinical trialsFast track designationHematologyDrug Policy, Pricing & ApprovalFDA drug approvalOrphan drug designationNovo NordiskPharmaceutical IndustryRare diseases00